Redox biology in normal cells and cancer: Restoring function of the redox/Fyn/c-Cbl pathway in cancer cells offers new approaches to cancer treatment

Free Radical Biology and Medicine

Volumn 79, Issue , 2015, Pages 300-323

  Noble, Mark ^a   Mayer Pröschel, Margot ^a   Li, Zaibo ^b   Dong, Tiefei ^c   Cui, Wanchang ^d   Pröschel, Christoph ^a   Ambeskovic, Ibro ^a   Dietrich, Joerg ^e   Han, Ruolan ^a   Yang, Yin Miranda ^a   Folts, Christopher ^a   Stripay, Jennifer ^a   Chen, Hsing Yu ^f   Stevens, Brett M ^g  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Basal like breast cancer; c Cbl; Glioblastoma; Oligodendrocyte type 2 astrocyte progenitor cell; Progenitor cell; Redox; Redox Fyn c Cbl pathway; Stem cell; Tamoxifen; Tumor initiating cell

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CBL PROTEIN; PROTEIN CDC42; PROTEIN KINASE FYN; TAMOXIFEN; CBL PROTEIN, HUMAN; FYN PROTEIN, HUMAN;

BASAL LIKE BREAST CANCER; CANCER CELL; CANCER THERAPY; CELL DIFFERENTIATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM; GLIOBLASTOMA; NON-TRANSFORMED CELL; NONHUMAN; OLIGODENDROGLIA; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; HUMAN; METABOLISM; NEOPLASMS; OXIDATION REDUCTION REACTION; PATHOLOGY;

ANIMALS; HUMANS; NEOPLASMS; OXIDATION-REDUCTION; PROTO-ONCOGENE PROTEINS C-CBL; PROTO-ONCOGENE PROTEINS C-FYN;

EID: 84923264470     PISSN: 08915849     EISSN: 18734596     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2014.10.860     Document Type: Review

References (399)

1. J.C. Louis, E. Magal, S. Takayama, and S. Varon CNTF protection of oligodendrocytes against natural and tumor necrosis factor-induced death Science 259 1993 689 692
2. M. Mayer, and M. Noble N-acetyl-L-cysteine is a pluripotent protector against cell death and enhancer of trophic factor-mediated cell survival in vitro Proc. Natl. Acad. Sci. USA 91 1994 7496 7500
3. R. Takano, S. Hisahara, K. Namikawa, H. Kiyama, H. Okano, and M. Miura Nerve growth factor protects oligodendrocytes from tumor necrosis factor-alpha-induced injury through Akt-mediated signaling mechanisms J Biol Chem 275 2000 16360 16365
4. W. Deng, H. Wang, P.A. Rosenberg, J.J. Volpe, and F.E. Jensen Role of metabotropic glutamate receptors in oligodendrocyte excitotoxicity and oxidative stress Proc.Natl. Acad. Sci. USA 101 2004 7751 7756
5. W. Deng, Q. Yue, P.A. Rosenberg, J.J. Volpe, and F.E. Jensen Oligodendrocyte excitotoxicity determined by local glutamate accumulation and mitochondrial function J Neurochem 98 2006 213 222
6. R. Fern, and T. Moller Rapid ischemic cell death in immature oligodendrocytes: a fatal glutamate release feedback loop J Neurosci 20 2000 34 42
7. P.L. Follett, W. Deng, W. Dai, D.M. Talos, L.J. Massillon, P.A. Rosenberg, J.J. Volpe, and F.E. Jensen Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate J Neurosci 24 2004 4412 4420
8. E.E. Kelland, and N.J. Toms Group I metabotropic glutamate receptors limit AMPA receptor-mediated oligodendrocyte progenitor cell death Eur. J. Pharmacol. 424 2001 R3 R4
9. C. Matute, M.V. Sanchez-Gomez, L. Martinez-Millan, and R. Miledi Glutamate receptor-mediated toxicity in optic nerve oligodendrocytes Proc Natl Acad Sci U S A 94 1997 8830 8835
10. P. Werner, D. Pitt, and C.S. Raine Glutamate excitotoxicity - a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis? Journal of neural transmission Supplementum 2000 375 385
11. J. Beck, P. Rondot, L. Catinot, E. Falcoff, H. Kirchner, and J. Wietzerbin Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta neurologica Scandinavica 78 1988 318 323
12. M. Chofflon, C. Juillard, P. Juillard, G. Gauthier, and G.E. Grau Tumor necrosis factor alpha production as a possible predictor of relapse in patients with multiple sclerosis European cytokine network 3 1992 523 531
13. P. Rieckmann, M. Albrecht, B. Kitze, T. Weber, H. Tumani, A. Broocks, W. Luer, A. Helwig, and S. Poser Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity Ann Neurol 37 1995 82 88
14. M. Chofflon, S. Roth, C. Juillard, A.M. Paunier, P. Juillard, D. Degroote, and G.E. Grau Tumor necrosis factor production capacity as a potentially useful parameter to monitor disease activity in multiple sclerosis European cytokine network 8 1997 253 257
15. A.R. Ferguson, R.N. Christensen, J.C. Gensel, B.A. Miller, F. Sun, E.C. Beattie, J.C. Bresnahan, and M.S. Beattie Cell death after spinal cord injury is exacerbated by rapid TNF alpha-induced trafficking of GluR2-lacking AMPARs to the plasma membrane J. Neurosci 28 2008 11391 11400
16. M.S. Beattie, G.E. Hermann, R.C. Rogers, and J.C. Bresnahan Cell death in models of spinal cord injury Progress in brain research 137 2002 37 47
17. K.B. Chen, K. Uchida, H. Nakajima, T. Yayama, T. Hirai, S. Watanabe, A.R. Guerrero, S. Kobayashi, W.Y. Ma, S.Y. Liu, and H. Baba Tumor necrosis factor-alpha antagonist reduces apoptosis of neurons and oligodendroglia in rat spinal cord injury Spine 36 2011 1350 1358
18. C. Matute, M. Domercq, and M.V. Sanchez-Gomez Glutamate-mediated glial injury: mechanisms and clinical importance Glia 53 2006 212 224
19. C. Matute, E. Alberdi, G. Ibarretxe, and M.V. Sanchez-Gomez Excitotoxicity in glial cells Eur. J. Pharmacol. 447 2002 239 246
20. C. Matute, E. Alberdi, M. Domercq, M.V. Sanchez-Gomez, A. Perez-Samartin, A. Rodriguez-Antiguedad, and F. Perez-Cerda Excitotoxic damage to white matter J. Anat. 210 2007 693 702
21. J.H. Yi, and A.S. Hazell Excitotoxic mechanisms and the role of astrocytic glutamate transporters in traumatic brain injury Neurochem. Int. 48 2006 394 403
22. E. Park, A.A. Velumian, and M.G. Fehlings The role of excitotoxicity in secondary mechanisms of spinal cord injury: a review with an emphasis on the implications for white matter degeneration J. Neurotrauma 21 2004 754 774
23. M. Kostic, N. Zivkovic, and I. Stojanovic Multiple sclerosis and glutamate excitotoxicity Reviews in the neurosciences 24 2013 71 88
24. C. Matute Glutamate and ATP signalling in white matter pathology J. Anat. 219 2011 53 64
25. A. Meister, and M.E. Anderson Glutathione Annu. Rev. Biochem. 52 1983 711 760
26. A. Meister Glutathione, ascorbate, and cellular protection Cancer Res. 54 1994 1969s 1975s
27. B.S. Winkler, S.M. Orselli, and T.S. Rex The redox couple between glutathione and ascorbic acid: a chemical and physiological perspective Free radical biology & medicine 17 1994 333 349
28. H. Sies Glutathione and its role in cellular functions Free radical biology & medicine 27 1999 916 921
29. H.J. Forman, H. Zhang, and A. Rinna Glutathione: overview of its protective roles, measurement, and biosynthesis Molecular aspects of medicine 30 2009 1 12
30. U. Ernsberger Role of neurotrophin signalling in the differentiation of neurons from dorsal root ganglia and sympathetic ganglia Cell and tissue research 336 2009 349 384
31. J. Smith, E. Ladi, M. Mayer-Proschel, and M. Noble Redox state is a central modulator of the balance between self-renewal and differentiation in a dividing glial precursor cell Proc Natl Acad Sci U S A 97 2000 10032 10037
32. M. Noble, C. Proschel, and M. Mayer-Proschel Getting a GR(i)P on oligodendrocyte development Dev Biol 265 2004 33 52
33. M.C. Raff, R.H. Miller, and M. Noble A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium Nature 303 1983 390 396
34. S. Temple Division and differentiation of isolated CNS blast cells in microculture Nature 340 1989 471 473
35. N. Ibarrola, M. Mayer-Pröschel, A. Rodriguez-Peña, and M. Noble Evidence for the existence of at least two timing mechanisms that contribute to oligodendrocyte generation in vitro Developmental Biology 180 1996 1 21
36. J. Power, M. Mayer-Proschel, J. Smith, and M. Noble Oligodendrocyte precursor cells from different brain regions express divergent properties consistent with the differing time courses of myelination in these regions Dev Biol 245 2002 362 375
37. M. Noble, K. Murray, P. Stroobant, M.D. Waterfield, and P. Riddle Platelet-derived growth factor promotes division and motility and inhibits premature differentiation of the oligodendrocyte/type-2 astrocyte progenitor cell Nature 333 1988 560 562
38. M.C. Raff, L. Lillien, W. Richardson, J.F. Burne, and M. Noble Platelet-derived growth factor from astrocytes drives the clock that times oligodendrocyte development in culture Nature 333 1988 562 565
39. W.D. Richardson, N. Pringle, M.J. Mosley, B. Westermark, and M. Dubois Dalcq A role for platelet-derived growth factor in normal gliogenesis in the central nervous system Cell 53 1988 309 319
40. P.L. Yakovlev, and A.R. Lecours The myelogenetic cycles of regional maturation of the brain A. Minkowski, Regional development of the brain in early life 1967 Blackwell Oxford 3 70 (al., e)
41. O. Bogler, D. Wren, S.C. Barnett, H. Land, and M. Noble Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells Proc Natl Acad Sci U S A 87 1990 6368 6372
42. B. Barres, M. Lazar, and M. Raff A novel role for thyroid hormone, glucocorticoids and retinoic acid in timing oligodendrocyte development Development 120 1994 1097 1108
43. P. Mabie, M. Mehler, R. Marmur, A. Papavasiliou, Q. Song, and J. Kessler Bone morphogenetic proteins induce astroglial differentiation of oligodendroglial-astroglial progenitor cells Neurosci 17 1997 4112 4120
44. O.W. Griffith, and A. Meister Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine) J. Biol. Chem. 254 1979 7558 7560
45. Z. Li, T. Dong, C. Proschel, and M. Noble Chemically diverse toxicants converge on Fyn and c-Cbl to disrupt precursor cell function PLoS Biol 5 2007 e35
46. J. Abe, and B.C. Berk Fyn and JAK2 mediate ras activation by reactive oxygen species J. Biol. Chem. 274 1999 21003 21010
47. J. Abe, M. Okuda, Q. Huang, M. Yoshizumi, and B.C. Berk Reactive oxygen species activate p90 ribosomal S6 kinase via Fyn and Ras J. Biol. Chem. 275 2000 1739 1748
48. S.P. Hehner, R. Breitfreutz, G. Shubinsky, H. Unsoeld, K. Schulze-Osthoff, M.L. Schmitz, and W. Dröge Enhancement of T cell receptor signaling by a mild oxidative shift in the intracellular thiol pool J. Immunol. 165 2000 4319 4328
49. A.R. Sanguinetti, H. Cao, and C. Corley Mastick Fyn is required for oxidative- and hyperosmotic-stress-induced tyrosine phosphorylation of caveolin-1 Biochem. J. 376 2003 159 168
50. E.A. Feshchenko, W.Y. Langdon, and A.Y. Tsygankov Fyn, Yes, and Syk phosphorylation sites in c-Cbl map to the same tyrosine residues that become phosphorylated in activated T cells J. Biol. Chem. 273 1998 8223 8331
51. S. Hunter, E.A. Burton, S.C. Wu, and S.M. Anderson Fyn associates with Cbl and phosphorylates tyrosine 731 in Cbl, a binding site for phosphatidylinositol 3-kinase J. Biol. Chem. 274 1999 2097 2106
52. C.K. Kassenbrock, S.F. Hunter, P. Garl, G.L. Johnson, and S.M. Anderson Inhibition of Src family kinases blocks epidermal growth factor (EGF)-induced activation of Akt, phosphorylation of c-Cbl, and ubiquitination of the EGF receptor J. Biol. Chem. 277 2002 24967 24975
53. A.Y. Tsygankov, S. Mahajan, J.E. Fincke, and J.B. Bolen Specific association of tyrosine-phosphorylated c-Cbl with Fyn tyrosine kinase in T cells J. Biol. Chem. 271 1996 27130 27137
54. S. Miyake, M.L.J. Lupher, B. Druke, and H. Band The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha Proc. Natl. Acad. Sci. USA 95 1998 7927 7932
55. S. Miyake, K.P. Mullane-Robinson, N.L. Lill, P. Douillard, and H. Band Cbl-mediated negative regulation of platelet-derived growth factor receptor-dependent cell proliferation. A critical role for Cbl tyrosine kinase-binding domain J. Bio.l Chem 274 1999 16619 16628
56. L. Duan, Y. Miura, M. Dimri, B. Majumder, I.L. Dodge, A.L. Reddi, A. Ghosh, N. Fernandes, P. Zhou, K. Mullane-Robinson, N. Rao, S. Donoghue, R.A. Rogers, D. Bowtell, M. Naramura, H. Gu, V. Band, and H. Band Cbl-mediated ubiquitinylation is required for lysosomal sorting of epidermal growth factor receptor but is dispensable for endocytosis J. Biol. Chem. 278 2003 28950 28960
57. S. Rosenkranz, Y. Ikuno, F.L. Leong, R.A. Klinghoffer, S. Miyake, H. Band, and A. Kazlauskas Src family kinases negatively regulate platelet-derived growth factor alpha receptor-dependent signaling and disease progression J. Biol. Chem. 275 2000 9620 9627
58. M.H. Schmidt, and I. Dikic The Cbl interactome and its functions Nat. Rev. Mol. Cell. Biol. 6 2005 907 919
59. T.E. Taher, E.P. Tjin, E.A. Beuling, J. Borst, M. Spaargaren, and S.T. Pals c-Cbl is involved in Met signaling in B cells and mediates hepatocyte growth factor-induced receptor ubiquitination J. Immunol. 169 2002 (3793-3780)
60. S. Zeng, Z. Xu, S. Lipkowitz, and J.B. Longley Regulation of stem cell factor receptor signaling by Cbl family proteins (Cbl-b/c-Cbl) Blood 105 2005 226 232
61. B. Sehat, S. Andersson, L. Girnita, and O. Larsson Identification of c-Cbl as a new ligase for insulin-like growth factor-I receptor with distinct roles from Mdm2 in receptor ubiquitination and endocytosis Cancer Res. 68 2008 5669 5677
62. B.M. Jehn, I. Dittert, S. Beyer, K. von der Mark, and W. Bielke c-Cbl binding and ubiquitin-dependent lysosomal degradation of membrane-associated Notch1 J. Biol. Chem. 277 2002 8033 8040
63. V. Chitalia, S. Shivanna, J. Martorell, R. Meyer, E. Edelman, and N. Rahimi c-Cbl, a ubiquitin E3 ligase that targets active beta-catenin: a novel layer of Wnt signaling regulation J Biol Chem 288 2013 23505 23517
64. J. Boonstra, and J.A. Post Molecular events associated with reactive oxygen species and cell cycle progression in mammalian cells Gene 337 2004 1 13
65. P.M. Burch, and N.H. Heintz Redox regulation of cell-cycle re-entry: cyclin D1 as a primary target for the mitogenic effects of reactive oxygen and nitrogen species Antioxid. Redox Signal. 7 2005 741 751
66. W.C. Burhans, and N.H. Heintz The cell cycle is a redox cycle: linking phase-specific targets to cell fate Free Radic. Biol. Med. 47 2009 1282 1293
67. E.H. Verbon, J.A. Post, and J. Boonstra The influence of reactive oxygen species on cell cycle progression in mammalian cells 511 2012 1 6
68. M.L. Lupher Jr, C.E. Andoniou, D. Bonita, S. Miyake, and H. Band The c-Cbl oncoprotein Int J Biochem Cell Biol 30 1998 439 444
69. M.L. Lupher Jr, N. Rao, M.J. Eck, and H. Band The Cbl protooncoprotein: a negative regulator of immune receptor signal transduction Immunol Today 20 1999 375 382
70. A. Sanjay, W.C. Horne, and R. Baron The Cbl family: ubiquitin ligases regulating signaling by tyrosine kinases Science's STKE: signal transduction knowledge environment PE40 2001 2001
71. N. Rao, I. Dodge, and H. Band The Cbl family of ubiquitin ligases: critical negative regulators of tyrosine kinase signaling in the immune system J Leukoc Biol 71 2002 753 763
72. I. Dikic, I. Szymkiewicz, and P. Soubeyran Cbl signaling networks in the regulation of cell function Cellular and molecular life sciences: CMLS 60 2003 1805 1827
73. C.B. Thien, and W.Y. Langdon Negative regulation of PTK signalling by Cbl proteins Growth Factors 23 2005 161 167
74. C.B. Thien, and W.Y. Langdon c-Cbl and Cbl-b ubiquitin ligases: substrate diversity and the negative regulation of signalling responses Biochem. J. 391 2005 153 166
75. P.E. Ryan, G.C. Davies, M.M. Nau, and S. Lipkowitz Regulating the regulator: negative regulation of Cbl ubiquitin ligases Trends Biochem. Sci. 31 2006 79 88
76. G. Swaminathan, and A.Y. Tsygankov The Cbl family proteins: ring leaders in regulation of cell signaling J. Cell Physiol. 209 2006 21 43
77. F. Keime-Guibert, M. Napolitano, and J.Y. Delattre Neurological complications of radiotherapy and chemotherapy J. Neurol. 245 1998 695 708
78. W.R. Shapiro, and D.F. Young Neurological complications of antineoplastic therapy Acta Neurol. Scand. Suppl. 100 1984 125 132
79. D.R. Macdonald Neurologic complications of chemotherapy Neurol. Clin. 9 1991 955 967
80. M. Poppelreuter, J. Weis, A.K. Külz, O. Tucha, K.W. Lange, and H.H. Bartsch Cognitive dysfunction and subjective complaints of cancer patients: a cross-sectional study in a cancer rehabilitation centre Eur. J. Cancer 40 2004 43 49
81. C.C. Verstappen, J.J. Heimans, K. Hoekman, and T.J. Postma Neurotoxic complications of chemotherapy in patients with cancer: clinical signs and optimal management Drugs 63 2003 1549 1563
82. A. Minisini, G. Atalay, A. Bottomley, F. Puglisi, M. Piccart, and L. Biganzoli What is the effect of systemic anticancer treatment on cognitive function? Lancet Oncol. 5 2004 273 282
83. E.J. Dropcho Neurotoxicity of cancer chemotherapy Semin. Neurol. 24 2004 419 426
84. J.S. Wefel, A.E. Kayl, and C.A. Meyers Neuropsychological dysfunction associated with cancer and cancer therapies: a conceptual review of an emerging target Br. J. Cancer. 90 2004 1691 1696
85. C.A. Meyers Neurocognitive dysfunction in cancer patients Oncology 14 2000 75 79
86. C.A. Meyers How chemotherapy damages the central nervous system J. Biol. 7 2008 e11
87. M. Monje, and J. Dietrich Cognitive side effects of cancer therapy demonstrate a functional role for adult neurogenesis Behavioural brain research 227 2012 376 379
88. R. Seigers, S.B. Schagen, O. Van Tellingen, and J. Dietrich Chemotherapy-related cognitive dysfunction: current animal studies and future directions Brain imaging and behavior 7 2013 453 459
89. J. Kaiser, C. Bledowski, and J. Dietrich Neural correlates of chemotherapy-related cognitive impairment Cortex; a journal devoted to the study of the nervous system and behavior 54C 2014 33 50
90. J.S. Wefel, R. Lenzi, R.L. Therlault, R.N. Davis, and C.A. Meyers The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma Cancer 100 2004 2292 2299
91. J.S. Wefel, A.K. Saleeba, A.U. Buzdar, and C.A. Meyers Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer Cancer 116 2010 3348 3356
92. C.A. Meyers, and J.L. Abbruzzese Cognitive functioning in cancer patients: effect of previous treatment Neurology 42 1992 434 436
93. F.S. van Dam, S.B. Schagen, M.J. Muller, W. Boogerd, E. vd Wall, M.E. Droogleever Fortuyn, and S. Rodenhuis Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy J Natl Cancer Inst 90 1998 210 218
94. S.B. Schagen, F.S., v., M.J. Muller, W. Boogerd, J. Lindeboom, and P.F., B. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma Cancer 85 1999 640 650
95. S.M. Stemmer, J.C. Stears, B.S. Burton, R.B. Jones, and J.H. Simon White matter changes in patients with breast cancer treated with high-dose chemotherapy and autologous bone marrow support AJNR Am J Neuroradiol 15 1994 1267 1273
96. M.S. Brown, S.M. Stemmer, J.H. Simon, J.C. Stears, R.B. Jones, P.J. Cagnoni, and J.L. Sheeder White matter disease induced by high-dose chemotherapy: longitudinal study with MR imaging and proton spectroscopy AJNR Am J Neuroradiol 19 1998 217 221
97. P.K. Duffner Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors Neurologist 10 2004 293 310
98. P.K. Duffner, M.E. Cohen, and M.S. Parker Prospective intellectual testing in children with brain tumors Ann. Neurol. 23 1988 575 579
99. P.K. Duffner, M.E. Cohen, and P.R.M. Thomas Late effects of treatment on the intelligence of children with posterior fossa tumors Cancer 51 1983 233 237
100. J.F. Hirsch, D. Renier, P. Czernichow, L. Benveniste, and A. Pierre-Kahn Medulloblastoma in childhood. Survival and functional results Acta Neurochirurgica 48 1979 1 15
101. R.J. Packer, J. Goldwein, H.S. Nicholson, L.G. Vezina, J.C. Allen, M.D. Ris, K. Muraszko, L.B. Rorke, W.M. Wara, B.H. Cohen, and J.M. Boyett Treatment of children with medulloblastoma with reduced-dose craniospinal radiation therapy and adjuvant chemotherapy: a Children's Cancer Group study J. Clin. Oncol. 17 1999 2127 2136
102. R.J. Packer, L.N. Sutton, T.E. Atkins, J. Radcliffe, G.R. Bunin, G. D'Angio, K.R. Siegel, and L. Schut A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2 year results J. Neurosurg. 70 1989 707 713
103. N. Peylan-Ramu, D.G. Poplack, P.A. Pizzo, B.T. Adornato, and G. DiChiro Abnormal CT scans of the brain in asymptomatic children with acute lymphocytic leukemia after prophylactic treatment of the central nervous system with radiation and intrathecal chemotherapy N. Engl. J. Med. 298 1978 815 818
104. A.J. Raimondi, and T. Tomita Advantages of 'total' resection of medulloblastoma and disadvantages of full head postoperative radiation therapy Childs Brain 5 1979 550 551
105. J.H. Rowland, O.J. Glidewell, R.F. Sibley, J.C. Holland, R. Tull, A. Berman, M.L. Brecher, M. Harris, A.S. Glickman, and E. Forman al.:, e. Effects of different forms of central nervous prophylaxis on neuropsychologic function in childhood leukemia J. Clin. Oncol. 2 1984 1327 1335
106. R.K. Mulhern, S.L. Palmer, W.E. Reddick, J.O. Glass, L.E. Kun, J. Taylor, J. Langston, and A. Gajjar Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss J. Clin. Oncol. 19 2001 472 479
107. R.K. Mulhern, R. W.E., S.L. Palmer, J.O. Glass, T.D. Elkin, L.E. Kun, J. Taylor, J. Langston, and A. Gajjar Neurocognitive deficits in medulloblastoma survivors and white matter loss Ann. Neurol. 46 1999 834 841
108. C.A. Moore-Maxwell, M.B. Datto, and C.M. Hulette Chemotherapy-induced toxic leukoencephalopathy causes a wide range of symptoms: a series of four autopsies Mod Pathol 17 2004 241 247
109. R. Bashir, F.H. Hochberg, R.M. Linggood, and K. Hottleman Pre-irradiation internal carotid artery BCNU in treatment of glioblastoma multiforme J. Neurosurg. 68 1988 917 919
110. C.M. Filley Toxic leukoencephalopathy Clin. Neuropharmacol. 22 1999 249 260
111. W.J. Baker, G.L.J. Royer, and R.B. Weiss Cytarabine and neurologic toxicity J. Clin. Oncol. 9 1991 679 693
112. H.A. Bygrave, J.I. Geh, Y. Jani, and R. Glynne-Jones Neurological complications of 5-fluorouracil chemotherapy: case report and review of the literature Clin. Oncol. (R. Coll. Radiol.) 10 1998 334 336
113. D.H. Moore, W.C.J. Fowler, and L.S. Crumpler 5-Fluorouracil neurotoxicity Gynecol. Oncol. 36 1990 152 154
114. M.K. Tuxen, and S.W. Hansen Neurotoxicity secondary to antineoplastic drugs Cancer Treat. Rev. 20 1994 191 214
115. S.M. Choi, S.H. Lee, Y.S. Yang, B.C. Kim, M.K. Kim, and K.H. Cho 5-fluorouracil-induced leukoencephalopathy in patients with breast cancer Journal of Korean medical science 16 2001 328 334
116. T.C. Chen, D.R. Hinton, L. Leichman, R.D. Atkinson, M.L. Apuzzo, and W.T. Couldwell Multifocal inflammatory leukoencephalopathy associated with levamisole and 5-fluorouracil: case report Neurosurgery 35 1994 1138 1142 (discussion 1142-1133)
117. N. Cossaart, K.S. SantaCruz, D. Preston, P. Johnson, and B.S. Skikne Fatal chemotherapy-induced encephalopathy following high-dose therapy for metastatic breast cancer: a case report and review of the literature Bone Marrow Transplant 31 2003 57 60
118. A.B. Fassas, A.M. Gattani, and S. Morgello Cerebral demyelination with 5-fluorouracil and levamisole Cancer Invest 12 1994 379 383
119. C. Fujimoto, K. Ito, S. Iwasaki, K. Nakao, and M. Sugasawa Reversible impairment of auditory callosal pathway in 5-fluorouracil-induced leukoencephalopathy: parallel changes in function and imaging Otol Neurotol 27 2006 716 719
120. C.C. Hook, D.W. Kimmel, L.K. Kvols, B.W. Scheithauer, P.A. Forsyth, J. Rubin, C.G. Moertel, and M. Rodriguez Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole Ann Neurol 31 1992 262 267
121. S. Ishibashi, H. Nishimura, and H. Mizusawa 5-FU-induced acute leukoencephalopathy Intern Med 43 2004 1009 1010
122. Z.H. Israel, A. Lossos, V. Barak, D. Soffer, and T. Siegal Multifocal demyelinative leukoencephalopathy associated with 5-fluorouracil and levamisole Acta Oncol 39 2000 117 120
123. D.W. Kimmel, and A.J. Schutt Multifocal leukoencephalopathy: occurrence during 5-fluorouracil and levamisole therapy and resolution after discontinuation of chemotherapy Mayo Clin Proc 68 1993 363 365
124. P. Critchley, R. Abbott, and F.J. Madden Multifocal inflammatory leukoencephalopathy developing in a patient receiving 5-fluorouracil and levamisole Clin Oncol (R Coll Radiol) 6 1994 406
125. D.S. Enterline, N.C. Davey, and R.D. Tien Neuroradiology case of the day. Multifocal inflammatory leukoencephalopathy due to treatment with 5-fluorouracil and levamisole AJR Am J Roentgenol 165 1995 214 215
126. A.T. Figueredo, S.E. Fawcet, D.W. Molloy, J. Dobranowski, and J.E. Paulseth Disabling encephalopathy during 5-fluorouracil and levamisole adjuvant therapy for resected colorectal cancer: a report of two cases Cancer Invest 13 1995 608 611
127. G. Galassi, G. Tassone, M. Sintini, M. Spagnoli, L. Bertolani, and L. Mavilla 5-Fluorouracil- and levamisole-associated multifocal leukoencephalopathy Eur Neurol 36 1996 244 246
128. G. Luppi, A. Zoboli, F. Barbieri, G. Crisi, L. Piccinini, and V. Silingardi Multifocal leukoencephalopathy associated with 5-fluorouracil and levamisole adjuvant therapy for colon cancer. A report of two cases and review of the literature. The INTACC. Intergruppo Nazionale Terpia Adiuvante Colon Carcinoma Ann Oncol 7 1996 412 415
129. C.L. Murray, W.J. Ford, K.K. Swenson, D. Heros, and P.W. Sperduto Multifocal inflammatory leukoencephalopathy after fluorouracil and levamisole therapy for colon cancer AJNR Am J Neuroradiol 18 1997 1591 1592
130. I.S. Neu Multifocal inflammatory leukencephalopathy caused by adjuvant therapy with 5-fluorouracil and levamisole after resection for an adenocarcinoma of the colon Acta neurologica Scandinavica 87 1993 70
131. D.M. Savarese, J. Gordon, T.W. Smith, N.S. Litofsky, R. Licho, R. Ragland, and L. Recht Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. The use of thallium SPECT imaging to assist in noninvasive diagnosis - a case report Cancer 77 1996 387 394
132. A. Fujikawa, K. Tsuchiya, S. Katase, Y. Kurosaki, and J. Hachiya Diffusion-weighted MR imaging of Carmofur-induced leukoencephalopathy Eur Radiol 11 2001 2602 2606
133. Y.H. Hwang, C.K. Suh, and S.P. Park Multifocal inflammatory leukoencephalopathy: use of thallium-201 SPECT and proton MRS Journal of Korean medical science 18 2003 621 624
134. S.S. Ki, J.M. Jeong, S.H. Kim, S.H. Jeong, J.H. Lee, C.J. Han, Y.C. Kim, J.O. Lee, and Y.J. Hong A case of neurotoxicity following 5-fluorouracil-based chemotherapy Korean J Intern Med 17 2002 73 77
135. W. Mak, P.W. Cheng, and R.T. Cheung Leukoencephalopathy following chemotherapy for colonic carcinoma Clin Radiol 56 2001 333 335
136. S. Ohara, R. Hayashi, S. Hata, N. Itoh, N. Hanyu, and K. Yamamoto Leukoencephalopathy induced by chemotherapy with tegafur, a 5-fluorouracil derivative Acta Neuropathol (Berl) 96 1998 527 531
137. N.A. Pirzada, I.I. Ali, and R.M. Dafer Fluorouracil-induced neurotoxicity Ann Pharmacother 34 2000 35 38
138. K.K. Tha, S. Terae, M. Sugiura, T. Nishioka, M. Oka, K. Kudoh, K. Kaneko, and K. Miyasaka Diffusion-weighted magnetic resonance imaging in early stage of 5-fluorouracil-induced leukoencephalopathy Acta neurologica Scandinavica 106 2002 379 386
139. V.C. Wu, J.W. Huang, H.C. Lien, S.T. Hsieh, H.M. Liu, C.C. Yang, Y.H. Lin, J.J. Hwang, and K.D. Wu Levamisole-induced multifocal inflammatory leukoencephalopathy: clinical characteristics, outcome, and impact of treatment in 31 patients Medicine (Baltimore) 85 2006 203 213
140. J. Dietrich, R. Han, Y. Yang, M. Mayer-Proschel, and M. Noble CNS progenitor cells and oligodendrocytes are targets of chemotherapeutic agents in vitro and in vivo J Biol 5 2006 22
141. R. Han, Y.M. Yang, J. Dietrich, A. Luebke, M. Mayer-Proschel, and M. Noble Systemic 5-fluorouracil treatment causes a syndrome of delayed myelin destruction in the central nervous system J Biol 7 2008 12
142. F. Dessi, H. Pollard, J. Moreau, Y. Ben-Ari, and C. Charriaut-Marlangue Cytosine arabinoside induces apoptosis in cerebellar neurons in culture J. Neurochem. 64 1995 1980 1987
143. H.M. Geller, K.-Y. Cheng, N.K. Goldsmith, A.A. Alejandro, A.-L. Zhang, E.J. Morris, and L. Grandison Oxidative stress mediates neuronal DNA damage and apoptosis in response to cytosine arabinoside J. Neurochem. 78 2001 265 275
144. D.P. Martin, T.L. Wallace, and E.M.J. Johnson Cytosine arabinoside kills postmitotic neurons in a fashion resembling trophic factor deprivation: evidence that a deoxycytidine-dependent process may be required for nerve growth factor signal transduction J. Neurosci. 10 1990 184 193
145. C. Sanz-Rodriguez, J. Boix, and J.X. Comella Cytosine arabinoside is neurotoxic to chick embryo spinal cord motoneurons in culture Neurosci. Lett. 223 1997 141 144
146. C.E. Tomkins, S.N. Edwards, and A.M. Tolkovsky Apoptosis is induced in post-mitotic rat sympathetic neurons by arabinosides and topoisomerase II inhibitors in the presence of NGF J. Cell Sci. 107 1994 1499 1507
147. A. Wick, W. Wick, J. Hirrlinger, E. Gerhardt, R. Dringen, J. Dichgans, M. Weller, and J.B. Schulz Chemotherapy-induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity J. Neurochem 91 2004 1067 1074
148. K.H. Cho, S.M. Choi, B.C. Kim, S.H. Lee, M.S. Park, M.K. Kim, and J.K. Kim 5-fluorouracil-induced oligodendrocyte death and inhibitory effect of cycloheximide, Trolox, and Z-VAD-FMK in murine cortical culture Cancer 100 2004 1484 1490
149. M. Yamada, H. Nakagawa, M. Fukushima, K. Shimizu, T. Hayakawa, and K. Ikenaka In vitro study on intrathecal use of 5-fluoro-2'-deoxyuridine (FdUrd) for meningeal dissemination of malignant brain tumors J. Neurooncol. 37 1998 115 121
150. D.H. Rowitch, Q.R. Lu, N. Kessaris, and W.D. Richardson An 'oligarchy' rules neural development Trends Neurosci 25 2002 417 422
151. S.E. Ross, M.E. Greenberg, and C.D. Stiles Basic helix-loop-helix factors in cortical development Neuron 39 2003 13 25
152. K.L. Ligon, S.P. Fancy, R.J. Franklin, and D.H. Rowitch Olig gene function in CNS development and disease Glia 54 2006 1 10
153. H. Li, and W.D. Richardson The evolution of Olig genes and their roles in myelination Neuron glia biology 4 2008 129 135
154. S. Mitew, C.M. Hay, H. Peckham, J. Xiao, M. Koenning, and B. Emery Mechanisms regulating the development of oligodendrocytes and central nervous system myelin Neuroscience 2013
155. C.B. Brezden, K.A. Phillips, M. Abdolell, T. Bunston, and I.F. Tannock Cognitive function in breast cancer patients receiving adjuvant chemotherapy Journal of clinical oncology: official journal of the American Society of Clinical Oncology 18 2000 2695 2701
156. M.E. Haykin, M. Gorman, J. van Hoff, R.K. Fulbright, and J.M. Baehring Diffusion-weighted MRI correlates of subacute methotrexate-related neurotoxicity J. Neurooncol. 76 2006 153 157
157. A. Shuper, B. Stark, L. Kornreich, I.J. Cohen, S. Aviner, A. Steinmetz, J. Stein, Y. Goshen, and I. Yaniv Methotrexate treatment protocols and the central nervous system: significant cure with significant neurotoxicity J. Child Neurol. 15 2000 573 580
158. W. Bruck, E. Heise, and R.L. Friede Leukoencephalopathy after cisplatin therapy Clin. Neuropathol. 8 1989 263 265
159. B.K. Kleinschmidt-DeMasters Intracarotid BCNU leukoencephalopathy Cancer 57 1986 1276 1280
160. S.A. Castellon, P.A. Ganz, J.E. Bower, L. Petersen, L. Abraham, and G.A. Greendale Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen J. Clin. Exp. Neuropsychol. 26 2004 955 969
161. D.H. Silverman, C.J. Dy, S.A. Castellon, J. Lai, B.S. Pio, L. Abraham, K. Waddell, L. Petersen, M.E. Phelps, and P.A. Ganz Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy Breast cancer research and treatment 103 2007 303 311
162. R.H. Herzig, G.P. Herzig, S.N. Wolff, J.D. Hines, J.W. Fay, and G.L. Phillips Central nervous system effects of high-dose cytosine arabinoside Semin. Oncol. 14 1987 21 24
163. R.H. Herzig, J.D. Hines, G.P. Herzig, S.N. Wolff, P.A. Cassileth, H.M. Lazarus, D.J. Adelstein, R.A. Brown, P.F. Coccia, and S. Strandjord Cerebellar toxicity with high-dose cytosine arabinoside J. Clin. Oncol. 5 1987 927 932
164. S.B. Schagen, M.J. Muller, W. Boogerd, G.J. Mellenbergh, and F.S. van Dam Change in cognitive function after chemotherapy: a prospective longitudinal study in breast cancer patients J. Natl. Cancer Inst. 98 2006 1742 1745
165. T.A. Ahles, and A. Saykin Cognitive effects of standard-dose chemotherapy in patients with cancer Cancer Invest. 19 2001 812 820
166. T.A. Ahles, A.J. Saykin, C.T. Furstenberg, B. Cole, L.A. Mott, I.K. Skalla, M.B. Whedon, S. Bivens, T. Mitchell, E.R. Greenberg, and P.M. Silberfarb Neuropsychologic impact of standard-dose systemic chemotherapy in long- term survivors of breast cancer and lymphoma J. Clin. Oncol. 20 2002 485 493
167. K.A. Phillips, and J. Bernhard Adjuvant breast cancer treatment and cognitive function: current knowledge and research directions J. Natl. Cancer Inst. 95 2003 190 197
168. R.A. Price, and P.A. Jamieson The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy Cancer 35 1975 306 318
169. M.C. Janelsins, J.A. Roscoe, M.J. Berg, B.D. Thompson, M.J. Gallaghe, G.R. Morrow, C.E. Heckler, P. Jean-Pierre, L.A. Opanashuk, and R.A. Gross IGF-1 partially restores chemotherapy-induced reductions in neural cell proliferation in adult C57BL/6 mice Cancer Invest. 28 2009 544 553
170. R.G. Mignone, and E.T. Weber Potent inhibition of cell proliferation in the hippocampal dentate gyrus of mice by the chemotherapeutic drug thioTEPA Brain Res. 1111 2006 26 29
171. C.M. Mondie, K.A. Vandergrift, C.L. Wilson, M.E. Gulinello, and E.T. Weber The chemotherapy agent, thioTEPA, yields long-term impairment of hippocampal cell proliferation and memory deficits but not depression-related behaviors of mice Behav. Brain Res. 209 2010 66 72
172. T.L. Briones, and J. Woods Chemotherapy-induced cognitive impairment is associated with decreases in cell proliferation and histone modifications BMC Neurosci 12 2011 124
173. L.A. Christie, M.M. Acharya, V.K. Parihar, A. Nguyen, V. Martirosian, and C.L. Limoli Impaired cognitive function and hippocampal neurogenesis following cancer chemotherapy Clinical cancer research: an official journal of the American Association for Cancer Research 18 2012 1954 1965
174. M. Eijkenboom, and F.J. Van Der Staay Spatial learning deficits in rats after injection of vincristine into the dorsal hippocampus Neuroscience 91 1999 1299 1313
175. M. ElBeltagy, S. Mustafa, J. Umka, L. Lyons, A. Salman, G.T. Chur-yoe, N. Bhalla, G. Bennett, and P.M. Wigmore Fluoxetine improves the memory deficits caused by the chemotherapy agent 5-fluorouracil Behavioural brain research 208 2010 112 117
176. M. ElBeltagy, S. Mustafa, J. Umka, L. Lyons, A. Salman, K. Dormon, C. Allcock, G. Bennett, and P. Wigmore The effect of 5-fluorouracil on the long term survival and proliferation of cells in the rat hippocampus Brain research bulletin 88 2012 514 518
177. G.K. Helal, A.M. Aleisa, O.K. Helal, S.S. Al-Rejaie, A.A. Al-Yahya, A.A. Al-Majed, and O.A. Al-Shabanah Metallothionein induction reduces caspase-3 activity and TNFalpha levels with preservation of cognitive function and intact hippocampal neurons in carmustine-treated rats Oxidative medicine and cellular longevity 2 2009 26 35
178. G. Joshi, S. Hardas, R. Sultana, D.K. St Clair, M. Vore, and D.A. Butterfield Glutathione elevation by gamma-glutamyl cysteine ethyl ester as a potential therapeutic strategy for preventing oxidative stress in brain mediated by in vivo administration of adriamycin: Implication for chemobrain J Neurosci Res 85 2007 497 503
179. G. Joshi, C.D. Aluise, M.P. Cole, R. Sultana, W.M. Pierce, M. Vore, D.K. St Clair, and D.A. Butterfield Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain Neuroscience 166 2010 796 807
180. G.W. Konat, M. Kraszpulski, I. James, H.T. Zhang, and J. Abraham Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats Metabolic brain disease 23 2008 325 333
181. B.W. Lau, S.Y. Yau, T.M. Lee, Y.P. Ching, S.W. Tang, and K.F. So Intracerebroventricular infusion of cytosine-arabinoside causes prepulse inhibition disruption Neuroreport 20 2009 371 377
182. C.Q. Li, D. Liu, L. Huang, H. Wang, J.Y. Zhang, and X.G. Luo Cytosine arabinoside treatment impairs the remote spatial memory function and induces dendritic retraction in the anterior cingulate cortex of rats Brain research bulletin 77 2008 237 240
183. Y. Li, V. Vijayanathan, M. Gulinello, and P.D. Cole Intrathecal methotrexate induces focal cognitive deficits and increases cerebrospinal fluid homocysteine Pharmacology, biochemistry, and behavior 95 2010 428 433
184. Y. Li, V. Vijayanathan, M.E. Gulinello, and P.D. Cole Systemic methotrexate induces spatial memory deficits and depletes cerebrospinal fluid folate in rats Pharmacology, biochemistry, and behavior 94 2010 454 463
185. P.E. Liedke, G.K. Reolon, B. Kilpp, A.L. Brunetto, R. Roesler, and G. Schwartsmann Systemic administration of doxorubicin impairs aversively motivated memory in rats Pharmacology, biochemistry, and behavior 94 2009 239 243
186. L. Lyons, M. Elbeltagy, G. Bennett, and P. Wigmore The effects of cyclophosphamide on hippocampal cell proliferation and spatial working memory in rat PLoS ONE 6 2011 e21445
187. L. Lyons, M. ElBeltagy, G. Bennett, and P. Wigmore Fluoxetine counteracts the cognitive and cellular effects of 5-fluorouracil in the rat hippocampus by a mechanism of prevention rather than recovery PLoS ONE 7 2012 e30010
188. S. Mustafa, A. Walker, G. Bennett, and P.M. Wigmore 5-Fluorouracil chemotherapy affects spatial working memory and newborn neurons in the adult rat hippocampus The European journal of neuroscience 28 2008 323 330
189. W. Rzeski, S. Pruskil, A. Macke, U. Felderhoff-Mueser, A.K. Reiher, F. Hoerster, C. Jansma, B. Jarosz, V. Stefovska, P. Bittigau, and C. Ikonomidou Anticancer agents are potent neurotoxins in vitro and in vivo Ann Neurol 56 2004 351 360
190. R. Seigers, and J.E. Fardell Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research Neuroscience and biobehavioral reviews 35 2011 729 741
191. R. Seigers, S.B. Schagen, W. Beerling, W. Boogerd, O. van Tellingen, F.S. van Dam, J.M. Koolhaas, and B. Buwalda Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat Behavioural brain research 186 2008 168 175
192. R. Seigers, S.B. Schagen, C.M. Coppens, P.J. van der Most, F.S. van Dam, J.M. Koolhaas, and B. Buwalda Methotrexate decreases hippocampal cell proliferation and induces memory deficits in rats Behavioural brain research 201 2009 279 284
193. R. Seigers, L. Pourtau, S.B. Schagen, F.S. van Dam, J.M. Koolhaas, J.P. Konsman, and B. Buwalda Inhibition of hippocampal cell proliferation by methotrexate in rats is not potentiated by the presence of a tumor Brain research bulletin 81 2010 472 476
194. R. Seigers, J. Timmermans, H.J. van der Horn, E.F. de Vries, R.A. Dierckx, L. Visser, S.B. Schagen, F.S. van Dam, J.M. Koolhaas, and B. Buwalda Methotrexate reduces hippocampal blood vessel density and activates microglia in rats but does not elevate central cytokine release Behavioural brain research 207 2010 265 272
195. J. Tangpong, S. Miriyala, T. Noel, C. Sinthupibulyakit, P. Jungsuwadee St, and D.K. Clair Doxorubicin-induced central nervous system toxicity and protection by xanthone derivative of Garcinia mangostana Neuroscience 175 2011 292 299
196. G. Winocur, M. Henkelman, J.M. Wojtowicz, H. Zhang, M.A. Binns, and I.F. Tannock The effects of chemotherapy on cognitive function in a mouse model: a prospective study Clinical cancer research: an official journal of the American Association for Cancer Research 18 2012 3112 3121
197. M. Yang, J.S. Kim, M.S. Song, S.H. Kim, S.S. Kang, C.S. Bae, J.C. Kim, H. Wang, T. Shin, and C. Moon Cyclophosphamide impairs hippocampus-dependent learning and memory in adult mice: Possible involvement of hippocampal neurogenesis in chemotherapy-induced memory deficits Neurobiology of learning and memory 93 2010 487 494
198. M. Yang, J.S. Kim, J. Kim, S.H. Kim, J.C. Kim, J. Kim, H. Wang, T. Shin, and C. Moon Neurotoxicity of methotrexate to hippocampal cells in vivo and in vitro Biochemical pharmacology 82 2011 72 80
199. M. Yang, J.S. Kim, J. Kim, S. Jang, S.H. Kim, J.C. Kim, T. Shin, H. Wang, and C. Moon Acute treatment with methotrexate induces hippocampal dysfunction in a mouse model of breast cancer Brain research bulletin 89 2012 50 56
200. C.M. Schilder, C. Seynaeve, L.V. Beex, W. Booerd, S.C. Linn, C.M. Gundy, H.M. Huizenga, J.W. Nortier, C.J. van de Velde, F.S. van Dam, and S.B. Schagen Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: Results from the neuropsychological side study of the tamoxifen and exemestane ajuvant multinational trial J. Clin. Oncol. 28 2010 1294 1300
201. M.A. Espeland, S.A. Shumaker, M. Limacher, S.R. Rapp, T.B. Bevers, D.H. Barad, L.H. Coker, S.A. Gaulssoin, M.L. Stefanick, D.S. Lane, P.M. Maki, and S.M. Resnick Relative effects of tamoxifen, raloxifene and conjugated equine estrogens on cognition J. Womens Health 19 2010 371 379
202. C.M. Bender, K.K. Paraska, S.M. Sereika, C.M. Ryan, and S.L. Berga Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review J. Pain Symptom Manage. 21 2001 407 424
203. J.L. Eberling, C. Wu, R. Tong-Turnbeaugh, and W.J. Jagust Estrogen- and tamoxifen-associated effects on brain structure and function Neuroimage 21 2004
204. J.L. Palmer, T. Trotter, A.A. Joy, and L.E. Carlson Cognitive effects of Tamoxifen in pre-menopausal women with breast cancer compared to healthy controls Journal of cancer survivorship: research and practice 2 2008 275 282
205. H.-Y. Chen, Y.M. Yang, R. Han, and M. Noble MEK1/2 inhibition suppresses tamoxifen toxicity on CNS oligodendrocyte progenitor cells J. Neurosci. 33 2013 15069 15074
206. P.A. Karplus, R.L. Krauth-Siegel, R.H. Schirmer, and G.E. Schulz Inhibition of human glutathione reductase by the nitrosourea drugs 1,3-bis(2-chloroethyl)-1-nitrosourea and 1-(2-chloroethyl)-3-(2-hydroxyethyl)-1-nitrosourea Eur. J. Biochem. 171 1988 193 198
207. A.A. Hercbergs, L.K. Goyal, J.H. Suh, S. Lee, C.A. Reddy, B.H. Cohen, G.H. Stevens, S.K. Reddy, D.M. Peereboom, P.J. Elson, M.K. Gupta, and G.H. Barnett Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: a phase I/II study Anticancer Res. 23 2003 617 626
208. E.A. Perez, D.R. Gandara, M.J. Edelman, R. O'Donnell, I.J. Lauder, and M. DeGregorio Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies Cancer Invest. 21 2003 1 6
209. S.J. O'Day, P.D. Boasberg, T.S. Kristedja, M. Martin, H.J. Wang, P. Fournier, M. Cabot, M.W. DeGregorio, and G. Gammon High-dose tamoxifen added to concurrent biochemotherapy with decrescendo interleukin-2 in patients with metastatic melanoma Cancer 2 2001 609 619
210. A. Hansmann, C. Adolph, T. Vogel, A. Unger, and G. Moeslein High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors Cancer 100 2004 612 620
211. A.A. Ezzat, E.M. Ibrahim, R.K. Stuart, D. Ajarim, S. Bazarbashi, M.O. El-Foudeh, M. Rahal, A. Al-Sayed, and J. Berry Adding high-dose tamoxifen to CHOP does not influence response or survival in aggressive non-Hodgkin's lymphoma: an interim analysis of a randomized phase III trial Med. Oncol. 17 2000 39 46
212. M. Hamilton, W. Dahut, O. Brawley, P. Davis, T. Wells-Jones, D. Kohler, P. Duray, D.J. Liewehr, N. Lakhani, S.M. Steinberg, W.D. Figg, and E. Reed A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer Acta Oncol. 42 2003 195 201
213. Y.S. Lu, C. Hsu, C.C. Li, S.H. Kuo, K.H. Yeh, C.H. Yang, C.H. Hsu, C.Y. Wu, and A.L. Cheng Phase II study of combination doxorubicin, interferon-alpha, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma Hepatogastroenterology 51 2004 815 819
214. G. Ferrandina, F.O. Ranelletti, L.M. Larocca, N. Maggiano, E. Fruscella, F. Legge, G. Santeusanio, A. Bombonati, S. Mancuso, and G. Scambia Tamoxifen modulates the expression of Ki67, apoptosis, and microvessel density in cervical cancer Clin. Cancer Res. 7 2001 2656 2661
215. B.L. Samuels, D.R. Hollis, G.L. Rosner, D.L. Trump, C.L. Shapiro, N.J. Vogelzang, and R.L. Schilsky Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study Clin. Cancer Res. 3 1997
216. K.H. Yeh, Y.S. Lu, C.H. Hsiao, and A.L. Cheng High-dose tamoxifen modulates drug resistance to doxorubicin, dacarbazine and ifosfamide in metastatic uterine leiomyosarcoma Anticancer Res. 23 2003 5133 5137
217. A. Kallio, A. Zheng, J. Dahllund, K.M. Heiskanen, and P. Harkonen Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells Apoptosis 10 2005 1395 1410
218. G.J. Zhang, I. Kimijima, M. Onda, M. Kanno, H. Sato, T. Watanabe, A. Tsuchiya, R. Abe, and S. Takenoshita Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-X(L), without alteration of p53 protein levels Clin. Cancer Res. 5 1999 2971 2977
219. A. Zheng, A. Kallio, and P. Härkönen Tamoxifen-induced rapid death of MCF-7 breast cancer cells is mediated via extracellularly signal-regulated kinase signaling and can be abrogated by estrogen Endocrinology 148 2007 2764 2777
220. I. Shin, and C.L. Arteaga Expression of active Akt protects against tamoxifen-induced apoptosis in MCF-7 Cells IUBMB Life 58 2006 664 669
221. E.R. Kisanga, J. Gjerde, A. Guerrieri-Gonzaga, F. Pigatto, A. Pesci-Feltri, C. Robertson, D. Serrano, G. Pelosi, A. Decensi, and E.A. Lien Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial Clin. Cancer Res. 10 2004 2336 2343
222. S.R.D. Johnston, B.P. Haynes, N.P.M. Sacks, J.A. McKinna, L.J. Griggs, M. Jarman, M. Baum, I.E. Smith, and M. Dowsett Effect of oestrogen receptor status and time on the intra-tumoral accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer Breast Cancer Res. Treat. 28 1993 241 250
223. A. Decensi, S. Gandini, A. Guerrieri-Gonzaga, H. Johansson, L. Manetti, B. Bonanni, M.T. Sandri, A. Barreca, A. Costa, C. Robertson, and E.A. Lien Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women J. Clin. Oncol. 17 1999 2633 2638
224. S. Mandlekar, and A.N. Kong Mechanisms of tamoxifen-induced apoptosis Apoptosis 6 2001 469 477
225. C. Ferlini, G. Scambia, M. Marone, M. Distefano, C. Gaggini, G. Ferrandina, A. Fattorossi, G. Isola, P. Benedetti Panici, and S. Mancuso Tamoxifen induces oxidative stress and apoptosis in oestrogen receptor-negative human cancer cell lines Br. J.Cancer 79 1999 257 263
226. U. Gundimeda, Z.H. Chen, and R. Gopalakrishna Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells J. Biol. Chem. 271 1996 13504 13514
227. B.M. Stevens, W. Cui, C.J. Folts, A.L. Bardin, K. Walter, E. Carson-Walter, A. Vescovi, and M. Noble Cool-1 mediated inhibition of c-Cbl modulates multiple critical properties of glioblastomas, including the ability to generate tumors in vivo Stem Cells 32 2014 1124 1135
228. R. Galli, E. Binda, U. Orfanelli, B. Cipelletti, A. Gritti, S. De Vitis, R. Fiocco, C. Foroni, F. Dimeco, and A. Vescovi Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma Cancer Res. 64 2004 7011 7021
229. E. Binda, A. Visioli, F. Giani, G. Lamorte, M. Copetti, K.L. Pitter, J.T. Huse, L. Cajola, N. Zanetti, F. Dimeco, L.M., A. De Filippis, G. Maira, C. Anile, P. De Bonis, B.A. Reynolds, E.B. Pasquale, and A.L. Vescovi The EphA2 Receptor Drives Self-Renewal and Tumorigenicity in Stem-like Tumor-Propagating Cells from Human Glioblastomas Cancer Cell 22 2012 765 780
230. M.V. Grandal, R. Zandi, M.W. Pedersen, B.M. Willumsen, B. van Deurs, and H.S. Poulsen EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes Carcinogenesis 28 2007 1408 1417
231. A. Slivka, M.B. Spina, and G. Cohen Reduced and oxidized glutathione in human and monkey brain Neurosci Lett 74 1987 112 118
232. W.J. Wu, S. Tu, and R.A. Cerione Activated Cdc42 sequesters c-Cbl and prevents EGF receptor degradation Cell 114 2003 715 725
233. D.S. Hirsch, Y. Shen, and W.J. Wu Growth and motility inhibition of breast cancer cells by epidermal growth factor receptor degradation is correlated with inactivation of Cdc42 Cancer Res. 66 2006 3523 3530
234. Q. Feng, D. Baird, X. Peng, J. Wang, T. Ly, J.L. Guan, and R.A. Cerione Cool-1 functions as an essential regulatory node for EGF receptor- and Src-mediated cell growth Nat. Cell Biol. 8 2006 945 956
235. G. Fritz, C. Brachetti, F. Bahlmann, M. Schmidt, and B. Kaina Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters Br, J. Cancer 87 2002 635 644
236. G. Fritz, I. Just, and B. Kaina Rho GTPases are over-expressed in human tumors Int. J. Cancer. 81 1999 682 687
237. S.H. Lee, M. Eom, S.J. Lee, S. Kim, H.J. Park, and D. Park BetaPix-enhanced p38 activation by Cdc42/Rac/PAK/MKK3/6-mediated pathway. Implication in the regulation of membrane ruffling Cancer Lett. 193 2003 99 107
238. M.H. Schmidt, K. Husnjak, I. Szymkiewicz, K. Haglund, and I. Dikic Cbl escapes Cdc42-mediated inhibition by downregulation of the adaptor molecule betaPix Oncogene 25 2006 3071 3078
239. E.M. Kepner, S.M. Yoder, E. Oh, M.A. Kalwat, Z. Wang, L.A. Quilliam, and D.C. Thurmond Cool-1/betaPIX functions as a guanine nucleotide exchange factor in the cycling of Cdc42 to regulate insulin secretion. American journal of physiology Endocrinology and metabolism 301 2011 E1072 1080
240. S. Kim, D. Kim, S.H. Lee, H. Park, H. Kim, and D. Park Molecular cloning of neuronally expressed mouse betaPix isoforms Biochem. Biophys. Res. Commun. 272 2000 721 725
241. H.-Y. Chen, Y.M. Yang, B. Stevens, and M. Noble Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumor initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells EMBO Mol. Med 5 2013 723 736
242. C.S. Pichot, C. Arvanitis, S.M. Hartig, S.A. Jensen, J. Bechill, S. Marzouk, J. Yu, J.A. Frost, and S.J. Corey Cdc42-interacting protein 4 promotes breast cancer cell invasion and formation of invadopodia through activation of N-WASp Cancer Res. 70 2010 8347 8356
243. P. Dombrosky-Ferlan, A. Grishin, R.J. Botelho, M. Sampson, L. Wang, W.A. Rudert, S. Grinstein, and S.J. Corey Felic (CIP4b), a novel binding partner with the Src kinase Lyn and Cdc42, localizes to the phagocytic cup Blood 101 2003 2804 2809
244. Z. Surviladze, A. Waller, J.J. Strouse, C. Bologa, O. Ursu, V. Salas, J.F. Parkinson, G.K. Phillips, E. Romero, A. Wandinger-Ness, L.A. Sklar, C. Schroeder, D. Simpson, J. Nöth, J. Wang, J. Golden, and J. Aubé A Potent and Selective Inhibitor of Cdc42 GTPase SourceProbe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US) 2010 Feb 27; 2010
245. P. Rizzo, H. Miao, G. D'Souza, C. Osipo, L.L. Song, J. Yun, H. Zhao, J. Mascarenhas, D. Wyatt, G. Antico, L. Hao, K. Yao, P. Rajan, C. Hicks, K. Siziopikou, S. Selvaggi, A. Bashir, D. Bhandari, A. Marchese, U. Lendahl, J.Z. Qin, D.A. Tonetti, K. Albain, B.J. Nickoloff, and L. Miele Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches Cancer Res. 68 2008 5226 5235
246. M. Baumann, M. Krause, and R. Hill Exploring the role of cancer stem cells in radioresistance Nature reviews. Cancer 8 2008 545 554
247. J.E. Visvader, and G.J. Lindeman Cancer stem cells in solid tumours: accumulating evidence and unresolved questions Nature reviews. Cancer 8 2008 755 768
248. C.A. O'Brien, A. Kreso, and J.E. Dick Cancer stem cells in solid tumors: an overview Seminars in radiation oncology 19 2009 71 77
249. M. Diehn, R.W. Cho, and M.F. Clarke Therapeutic implications of the cancer stem cell hypothesis Seminars in radiation oncology 19 2009 78 86
250. A. Scopelliti, P. Cammareri, V. Catalano, V. Saladino, M. Todaro, and G. Stassi Therapeutic implications of Cancer Initiating Cells Expert opinion on biological therapy 9 2009 1005 1016
251. J.M. Rosen, and C.T. Jordan The increasing complexity of the cancer stem cell paradigm Science 324 2009 1670 1673
252. P.B. Gupta, C.L. Chaffer, and R.A. Weinberg Cancer stem cells: mirage or reality? Nat Med 15 2009 1010 1012
253. N.Y. Frank, T. Schatton, and M.H. Frank The therapeutic promise of the cancer stem cell concept The Journal of clinical investigation 120 2010 41 50
254. F. Wan, S. Zhang, R. Xie, B. Gao, B. Campos, C. Herold-Mende, and T. Lei The utility and limitations of neurosphere assay, CD133 immunophenotyping and side population assay in glioma stem cell research Brain Pathol 20 2010 877 889
255. M. Greaves Cancer stem cells: back to Darwin? Seminars in cancer biology 20 2010 65 70
256. L. Cheng, S. Bao, and J.N. Rich Potential therapeutic implications of cancer stem cells in glioblastoma Biochemical pharmacology 80 2010 654 665
257. A.L. Stratford, K. Reipas, C. Maxwell, and S.E. Dunn Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer Expert reviews in molecular medicine 12 2010 e22
258. B.K. Garvalov, and T. Acker Cancer stem cells: a new framework for the design of tumor therapies J Mol Med (Berl) 89 2011 95 107
259. R.C. D'Angelo, and M.S. Wicha Stem cells in normal development and cancer Progress in molecular biology and translational science 95 2010 113 158
260. C. Blanpain, M. Mohrin, P.A. Sotiropoulou, and E. Passegue DNA-damage response in tissue-specific and cancer stem cells Cell Stem Cell 8 2011 16 29
261. S. Soltanian, and M.M. Matin Cancer stem cells and cancer therapy Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine 32 2011 425 440
262. H. Clevers The cancer stem cell: premises, promises and challenges Nat Med 17 2011 313 319
263. Z.A. Rasheed, J. Kowalski, B.D. Smith, and W. Matsui Concise review: Emerging concepts in clinical targeting of cancer stem cells Stem Cells 29 2011 883 887
264. F.M. Frame, and N.J. Maitland Cancer stem cells, models of study and implications of therapy resistance mechanisms Advances in experimental medicine and biology 720 2011 105 118
265. A. Pietras Cancer stem cells in tumor heterogeneity Advances in cancer research 112 2011 255 281
266. G. Ghiaur, J. Gerber, and R.J. Jones Concise review: Cancer stem cells and minimal residual disease Stem Cells 30 2012 89 93
267. Y. Li, and J. Laterra Cancer stem cells: distinct entities or dynamically regulated phenotypes? Cancer research 72 2012 576 580
268. D.G. Tang Understanding cancer stem cell heterogeneity and plasticity Cell research 22 2012 457 472
269. J.A. McCubrey, L.S. Steelman, S.L. Abrams, N. Misaghian, W.H. Chappell, J. Basecke, F. Nicoletti, M. Libra, G. Ligresti, F. Stivala, D. Maksimovic-Ivanic, S. Mijatovic, G. Montalto, M. Cervello, P. Laidler, A. Bonati, C. Evangelisti, L. Cocco, and A.M. Martelli Targeting the cancer initiating cell: the ultimate target for cancer therapy Current pharmaceutical design 18 2012 1784 1795
270. J.A. Magee, E. Piskounova, and S.J. Morrison Cancer stem cells: impact, heterogeneity, and uncertainty Cancer Cell 21 2012 283 296
271. J.E. Visvader, and G.J. Lindeman Cancer stem cells: current status and evolving complexities Cell Stem Cell 10 2012 717 728
272. M. Podberezin, J. Wen, and C.C. Chang Cancer stem cells: a review of potential clinical applications Archives of pathology & laboratory medicine 137 2013 1111 1116
273. N.D. Marjanovic, R.A. Weinberg, and C.L. Chaffer Cell plasticity and heterogeneity in cancer Clinical chemistry 59 2013 168 179
274. P. Valent, D. Bonnet, S. Wohrer, M. Andreeff, M. Copland, C. Chomienne, and C. Eaves Heterogeneity of neoplastic stem cells: theoretical, functional, and clinical implications Cancer research 73 2013 1037 1045
275. E.M.F. De Sousa, L. Vermeulen, E. Fessler, and J.P. Medema Cancer heterogeneity - a multifaceted view EMBO Rep 14 2013 686 695
276. C.E. Meacham, and S.J. Morrison Tumour heterogeneity and cancer cell plasticity Nature 501 2013 328 337
277. S. Dawood Triple-negative breast cancer: epidemiology and management options Drugs 70 2010 2247 2258
278. J. Foley, N.K. Nickerson, S. Nam, K.T. Allen, J.L. Gilmore, K.P. Nephew, and D.J.n. Riese EGFR signaling in breast cancer: bad to the bone Semin. Cell. Dev. Biol. 21 2010 951 960
279. R. Saxena, and A. Dwivedi ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective Med. Res. Rev. 32 2012 166 215
280. H. Harrison, G. Farnie, S.J. Howell, R.E. Rock, S. Stylianou, K.R. Brennan, N.J. Bundred, and R.B. Clarke Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor Cancer Res. 70 2010 709 718
281. S. Gastaldi, P.M. Comoglio, and L. Trusolino The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res. 12 2010 e208
282. B.W. Purow, R.M. Haque, M.W. Noel, Q. Su, M.J. Burdick, J. Lee, T. Sundaresan, S. Pastorino, J.K. Park, I. Mikolaenko, D. Maric, C.G. Eberhart, and H.A. Fine Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation Cancer Res. 65 2005 2353 2363
283. M. Kanamori, T. Kawaguchi, J.M. Nigro, B.G. Feuerstein, M.S. Berger, L. Miele, and R.O. Pieper Contribution of Notch signaling activation to human glioblastoma multiforme J. Neurosurg. 106 2007 417 427
284. X. Fan, L. Khaki, T.S. Zhu, M.E. Soules, C.E. Talsma, N. Gul, C. Koh, J. Zhang, Y.M. Li, J. Maciaczyk, G. Nikkhah, F. Dimeco, S. Piccirillo, A.L. Vescovi, and C.G. Eberhart NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts Stem Cells 28 2010 5 16
285. Y. Li, A. Li, M. Glas, B. Lal, M. Ying, Y. Sang, S. Xia, D. Trageser, H. Guerrero-Cazares, C.G. Eberhart, A. Quinones-Hinojosa, B. Scheffler, and J. Laterra c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype Proc Natl Acad Sci U S A 108 2011 9951 9956
286. K.M. Joo, J. Jin, E. Kim, K. Ho Kim, Y. Kim, B. Gu Kang, Y.J. Kang, J.D. Lathia, K.H. Cheong, P.H. Song, H. Kim, H.J. Seol, D.S. Kong, J.I. Lee, J.N. Rich, J. Lee, and D.H. Nam MET signaling regulates glioblastoma stem cells Cancer research 72 2012 3828 3838
287. K.H. Kim, H.J. Seol, E.H. Kim, J. Rheey, H.J. Jin, Y. Lee, K.M. Joo, J. Lee, and D.H. Nam Wnt/beta-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells Neuro-oncology 15 2013 161 171
288. C. Li, J.J. Wu, M. Hynes, J. Dosch, B. Sarkar, T.H. Welling, M. Pasca di Magliano, and D.M. Simeone c-Met is a marker of pancreatic cancer stem cells and therapeutic target Gastroenterology 141 2218-2227 2011 e2215
289. F. De Bacco, E. Casanova, E. Medico, S. Pellegatta, F. Orzan, R. Albano, P. Luraghi, G. Reato, A. D'Ambrosio, P. Porrati, M. Patane, E. Maderna, B. Pollo, P.M. Comoglio, G. Finocchiaro, and C. Boccaccio The MET oncogene is a functional marker of a glioblastoma stem cell subtype Cancer research 72 2012 4537 4550
290. M. Herreros-Villanueva, A. Zubia-Olascoaga, and L. Bujanda c-Met in pancreatic cancer stem cells: therapeutic implications World journal of gastroenterology: WJG 18 2012 5321 5323
291. C. Hage, V. Rausch, N. Giese, T. Giese, F. Schonsiegel, S. Labsch, C. Nwaeburu, J. Mattern, J. Gladkich, and I. Herr The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer Cell death & disease 4 2013 e627
292. M. Yashiro, T. Nishii, T. Hasegawa, T. Matsuzaki, T. Morisaki, T. Fukuoka, and K. Hirakawa A c-Met inhibitor increases the chemosensitivity of cancer stem cells to the irinotecan in gastric carcinoma British journal of cancer 109 2013 2619 2628
293. G.C. Chu, H.E. Zhau, R. Wang, A. Rogatko, X. Feng, M. Zayzafoon, Y. Liu, M.C. Farach-Carson, S. You, J. Kim, M.R. Freeman, and L.W. Chung RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization Endocrine-related cancer 21 2014 311 326
294. Z. Wang, A. Ahmad, Y. Li, A.S. Azmi, L. Miele, and F.H. Sarkar Targeting notch to eradicate pancreatic cancer stem cells for cancer therapy Anticancer research 31 2011 1105 1113
295. J. Wang, C. Wang, Q. Meng, S. Li, X. Sun, Y. Bo, and W. Yao siRNA targeting Notch-1 decreases glioma stem cell proliferation and tumor growth Molecular biology reports 39 2012 2497 2503
296. J. Tatarek, K. Cullion, T. Ashworth, R. Gerstein, J.C. Aster, and M.A. Kelliher Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL Blood 118 2011 1579 1590
297. J. Wang, B.A. Sullenger, and J.N. Rich Notch signaling in cancer stem cells Advances in experimental medicine and biology 727 2012 174 185
298. S. Ponnurangam, J.M. Mammen, S. Ramalingam, Z. He, Y. Zhang, S. Umar, D. Subramaniam, and S. Anant Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells Molecular cancer therapeutics 11 2012 963 972
299. C.S. Muller Notch signaling and malignant melanoma Advances in experimental medicine and biology 727 2012 258 264
300. S. Yu, R. Zhang, F. Liu, H. Wang, J. Wu, and Y. Wang Notch inhibition suppresses nasopharyngeal carcinoma by depleting cancer stem-like side population cells Oncology reports 28 2012 561 566
301. S.M. McAuliffe, S.L. Morgan, G.A. Wyant, L.T. Tran, K.W. Muto, Y.S. Chen, K.T. Chin, J.C. Partridge, B.B. Poole, K.H. Cheng, J. Daggett Jr, K. Cullen, E. Kantoff, K. Hasselbatt, J. Berkowitz, M.G. Muto, R.S. Berkowitz, J.C. Aster, U.A. Matulonis, and D.M. Dinulescu Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy Proc Natl Acad Sci U S A 109 2012 E2939 2948
302. C. Cai, and X. Zhu The Wnt/beta-catenin pathway regulates self-renewal of cancer stem-like cells in human gastric cancer Molecular medicine reports 5 2012 1191 1196
303. T.K. Fung, A. Gandillet, and C.W. So Selective treatment of mixed-lineage leukemia leukemic stem cells through targeting glycogen synthase kinase 3 and the canonical Wnt/beta-catenin pathway Current opinion in hematology 19 2012 280 286
304. A. Gong, and S. Huang FoxM1 and Wnt/beta-catenin signaling in glioma stem cells Cancer research 72 2012 5658 5662
305. J.D. Holland, A. Klaus, A.N. Garratt, and W. Birchmeier Wnt signaling in stem and cancer stem cells Current opinion in cell biology 25 2013 254 264
306. Z. Xia, P. Wei, H. Zhang, Z. Ding, L. Yang, Z. Huang, and N. Zhang AURKA governs self-renewal capacity in glioma-initiating cells via stabilization/activation of beta-catenin/Wnt signaling Molecular cancer research: MCR 11 2013 1101 1111
307. Y. Cheng, A.K. Cheung, J.M. Ko, Y.P. Phoon, P.M. Chiu, P.H. Lo, M.L. Waterman, and M.L. Lung Physiological beta-catenin signaling controls self-renewal networks and generation of stem-like cells from nasopharyngeal carcinoma BMC cell biology 14 2013 44
308. Y. Atlasi, L. Looijenga, and R. Fodde Cancer stem cells, pluripotency, and cellular heterogeneity: a WNTer perspective Current topics in developmental biology 107 2014 373 404
309. J. Mao, S. Fan, W. Ma, P. Fan, B. Wang, J. Zhang, H. Wang, B. Tang, Q. Zhang, X. Yu, L. Wang, B. Song, and L. Li Roles of Wnt/beta-catenin signaling in the gastric cancer stem cells proliferation and salinomycin treatment Cell death & disease 5 2014 e1039
310. J. Tang, Z.H. Tao, D. Wen, J.L. Wan, D.L. Liu, S. Zhang, J.F. Cui, H.C. Sun, L. Wang, J. Zhou, J. Fan, and W. Wu Z. miR-612 suppresses the stemness of liver cancer via Wnt/beta-catenin signaling Biochemical and biophysical research communications 447 2014 210 215
311. C.L. Arteaga, M.X. Sliwkowski, C.K. Osborne, E.A. Perez, F. Puglisi, and L. Gianni Treatment of HER2-positive breast cancer: current status and future perspectives Nat. Rev. Clin. Oncol. 9 2011 16 32
312. S.A. Hurvitz, Y. Hu, N. O'Brien, and R.S. Finn Current approaches and future directions in the treatment of HER2-positive breast cancer Cancer Treat Rev. 2012
313. H.M. Stern Improving treatment of HER2-positive cancers: opportunities and challenges Sci. Transl. Med. 4 2012 (127rv122)
314. G. Levkowitz, L.N. Klapper, E. Tzahar, A. Freywald, M. Sela, and Y. Yarden Coupling of the c-Cbl protooncogene product to ErbB-1/EGF-receptor but not to other ErbB proteins Oncogene 12 1996 1117 1125
315. A. Mancini, A. Koch, R. Wilms, and T. Tamura c-Cbl associates directly with the C-terminal tail of the receptor for the macrophage colony-stimulating factor, c-Fms, and down-modulates this receptor but not the viral oncogene v-Fms J Biol Chem 277 2002 14635 14640
316. J.T. Reilly FLT3 and its role in the pathogenesis of acute myeloid leukaemia Leukemia & lymphoma 44 2003 1 7
317. W.H. Lin, W.T. Jiaang, C.W. Chen, K.J. Yen, S.Y. Hsieh, S.C. Yen, C.P. Chen, K.Y. Chang, C.Y. Chang, T.Y. Chang, Y.L. Huang, T.K. Yeh, Y.S. Chao, C.T. Chen, and J.T. Hsu BPR1J-097, a novel FLT3 kinase inhibitor, exerts potent inhibitory activity against AML British journal of cancer 106 2012 475 481
318. H.K. Lee, H.W. Kim, I.Y. Lee, J. Lee, J. Lee, D.S. Jung, S.Y. Lee, S.H. Park, H. Hwang, J.S. Choi, J.H. Kim, S.W. Kim, J.K. Kim, J. Cools, J.S. Koh, and H.J. Song G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia Blood 123 2014 2209 2219
319. K.S. Smalley, V.K. Sondak, and J.S. Weber c-KIT signaling as the driving oncogenic event in sub-groups of melanomas Histology and histopathology 24 2009 643 650
320. S. Sartini, B. Dario, M. Morelli, F. Da Settimo, and C. La Motta Receptor tyrosine kinase kit and gastrointestinal stromal tumours: an overview Current medicinal chemistry 18 2011 2893 2903
321. M.A. Postow, and R.D. Carvajal Therapeutic implications of KIT in melanoma Cancer J 18 2012 137 141
322. L.K. Ashman, and R. Griffith Therapeutic targeting of c-KIT in cancer Expert opinion on investigational drugs 22 2013 103 115
323. K. Stankov, S. Popovic, and M. Mikov C-KIT Signaling in Cancer Treatment Current pharmaceutical design 2013
324. A. De Luca, M.R. Maiello, A. D'Alessio, M. Pergameno, and N. Normanno The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches Expert Opin. Ther. Targets 16 Suppl 2 2012 S17 27
325. J.K. Morrow, L. Du-Cuny, L. Chen, E.J. Meuillet, E.A. Mash, G. Powis, and S. Zhang Recent development of anticancer therapeutics targeting Akt. Recent Pat Anticancer Drug Discov 6 2011 146 159
326. L. Nogueira, P. Ruiz-Ontanon, A. Vazquez-Barquero, F. Moris, and J.L. Fernandez-Luna The NFkappaB pathway: a therapeutic target in glioblastoma Oncotarget 2 2011 646 653
327. P. Brescia, B. Ortensi, L. Fornasari, D. Levi, G. Broggi, and G. Pelicci CD133 is essential for glioblastoma stem cell maintenance Stem Cells 31 2013 857 869
328. G. Farnie, R.B. Clarke, K. Spence, N. Pinnock, K. Brennan, N.G. Anderson, and N.J. Bundred Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways J. Natl. Cancer Inst. 99 2007 616 627
329. D. Brehmer, Z. Greff, K. Godl, S. Blencke, A. Kurtenbach, M. Weber, S. Müller, B. Klebl, M. Cotten, G. Kéri, J. Wissing, and H. Daub Cellular targets of gefitinib Cancer Res. 65 2005 379 382
330. I. Dikic, and M.H. Schmidt Malfunctions within the Cbl interactome uncouple receptor tyrosine kinases from destructive transport European journal of cell biology 2007
331. S. Lipkowitz, and A.M. Weissman RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis Nat. Rev. Cancer. 11 2011 629 643
332. Q. Feng, D. Baird, S. Yoo, M. Antonyak, and R.A. Cerione Phosphorylation of the cool-1/beta-Pix protein serves as a regulatory signal for the migration and invasive activity of Src-transformed cells J. Biol. Chem. 285 2010 18806 18816
333. R. Ito, H. Nakayama, K. Yoshida, S. Matsumura, N. Oda, and W. Yasui Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma Virchows Archiv. 444 2004 324 331
334. K.S. Hill, M. Lorinczi, and L.A. Elferink Altered down regulation of the receptor tyrosine kinase met in pancreatic adenocarcinoma cells J. Exp. Ther. Oncol 8 2010 297 312
335. M.H. Schmidt, D. Hoeller, J. Yu, F.B. Furnari, W.K. Cavenee, I. Dikic, and O. Bogler Alix/AIP1 antagonizes epidermal growth factor receptor downregulation by the Cbl-SETA/CIN85 complex Molecular and cellular biology 24 2004 8981 8993
336. M.H. Schmidt, B. Chen, L.M. Randazzo, and O. Bogler SETA/CIN85/Ruk and its binding partner AIP1 associate with diverse cytoskeletal elements, including FAKs, and modulate cell adhesion J Cell Sci 116 2003 2845 2855
337. M.L. Loh, D.S. Sakai, C. Flotho, M. Kang, M. Fliegauf, S. Archambeault, C.G. Mullighan, L. Chen, E. Bergstraesser, C.E. Bueso-Ramos, P.D. Emanuel, H. Hasle, J.P. Issa, M.M. van den Heuvel-Eibrink, F. Locatelli, J. Stary, M. Trebo, M. Wlodarski, M. Zecca, K.M. Shannon, and C.M. Niemeyer Mutations in CBL occur frequently in juvenile myelomonocytic leukemia Blood 114 2009 1859 1863
338. M.A. Caligiuri, R. Briesewitz, J. Yu, L. Wang, M. Wei, K.J. Arnoczky, T.B. Marburger, J. Wen, D. Perrotti, C.D. Bloomfield, and S.P. Whitman Novel c-CBL and CBL-B ubiquitin ligase mutations in human acute myeloid leukemia Blood 2007
339. Y.H. Tan, S. Krishnaswamy, S. Nandi, R. Kanteti, S. Vora, K. Onel, R. Hasina, F.Y. Lo, E. El-Hashani, G. Cervantes, M. Robinson, H.S. Hsu, S.C. Kales, S. Lipkowitz, T. Karrison, M. Sattler, E.E. Vokes, Y.C. Wang, and R. Salgia CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases PLoS One 5 2010 e8972
340. S. Ogawa, L.Y. Shih, T. Suzuki, M. Otsu, H. Nakauchi, H.P. Koeffler, and M. Sanada Deregulated intracellular signaling by mutated c-CBL in myeloid neoplasms Clin. Cancer Res. 16 2010 3825 3831
341. S.C. Kales, P.E. Ryan, M.M. Nau, and S. Lipkowitz Cbl and human myeloid neoplasms: the Cbl oncogene comes of age Cancer Res. 70 2010 4789 4794
342. M. Sanada, T. Suzuki, L.Y. Shih, M. Otsu, M. Kato, S. Yamazaki, A. Tamura, H. Honda, M. Sakata-Yanagimoto, K. Kumano, H. Oda, T. Yamagata, J. Takita, N. Gotoh, K. Nakazaki, N. Kawamata, M. Onodera, M. Nobuyoshi, Y. Hayashi, H. Harada, M. Kurokawa, S. Chiba, H. Mori, K. Ozawa, M. Omine, H. Hirai, H. Nakauchi, H.P. Koeffler, and S. Ogawa Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms Nature 460 2009 904 908
343. G. Levkowitz, S. Oved, L.N. Klapper, D. Harari, S. Lavi, M. Sela, and Y. Yarden c-Cbl is a suppressor of the neu oncogene J Biol Chem 275 2000 35532 35539
344. A.J. Montero, and J. Jassem Cellular redox pathways as a therapeutic target in the treatment of cancer Drugs 71 2011 1385 1396
345. J. Fang, T. Seki, and H. Maeda Therapeutic strategies by modulating oxygen stress in cancer and inflammation Adv. Drug Deliv. Rev. 61 2009 290 302
346. C.M. Cabello, W.B. Bair 3rd, and G.T. Wondrak Experimental therapeutics: targeting the redox Achilles heel of cancer Curr Opin Investig Drugs 8 2007 1022 1037
347. J. Fang, H. Nakamura, and A.K. Iyer Tumor-targeted induction of oxystress for cancer therapy Journal of drug targeting 15 2007 475 486
348. J. Wang, and J. Yi Cancer cell killing via ROS: to increase or decrease, that is the question Cancer biology & therapy 7 2008 1875 1884
349. R. Beck, N. Dejeans, C. Glorieux, R.C. Pedrosa, D. Vasquez, J.A. Valderrama, P.B. Calderon, and J. Verrax Molecular chaperone Hsp90 as a target for oxidant-based anticancer therapies Current medicinal chemistry 18 2011 2816 2825
350. R.H. Engel, and A.M. Evens Oxidative stress and apoptosis: a new treatment paradigm in cancer Front. Biosci. 11 2006 300 312
351. J.D. Pennington, T.J. Wang, P. Nguyen, L. Sun, K. Bisht, D. Smart, and D. Gius Redox-sensitive signaling factors as a novel molecular targets for cancer therapy 8 2005 322 330
352. A. Acharya, I. Das, D. Chandhok, and T. Saha Redox regulation in cancer: a double-edged sword with therapeutic potential Oxidative medicine and cellular longevity 3 2010 23 34
353. M. Diehn, R.W. Cho, N.A. Lobo, T. Kalisky, M.J. Dorie, A.N. Kulp, D. Qian, J.S. Lam, L.E. Ailles, M. Wong, B. Joshua, M.J. Kaplan, I. Wapnir, F.M. Dirbas, G. Somlo, C. Garberoglio, B. Paz, J. Shen, S.K. Lau, S.R. Quake, J.M. Brown, I.L. Weissman, and M.F. Clarke Association of reactive oxygen species levels and radioresistance in cancer stem cells Nature 458 2009 780 783
354. E.D. Lagadinou, A. Sach, K. Callahan, R.M. Rossi, S.J. Neering, M. Minhajuddin, J.M. Ashton, S. Pei, V. Grose, K.M. O'Dwyer, J.L. Liesveld, P.S. Brookes, M.W. Becker, and C.T. Jordan BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells Cell Stem Cell 12 2013 329 341
355. E. Sugihara, and H. Saya Complexity of cancer stem cells. International journal of cancer Journal international du cancer 132 2013 1249 1259
356. N. Traverso, R. Ricciarelli, M. Nitti, B. Marengo, A.L. Furfaro, M.A. Pronzato, U.M. Marinari, and C. Domenicotti Role of glutathione in cancer progression and chemoresistance Oxidative medicine and cellular longevity 2013 972913 (2013)
357. P. Calvert, K.S. Yao, T.C. Hamilton, and P.J. O'Dwyer Clinical studies of reversal of drug resistance based on glutathione Chemico-biological interactions 111-112 1998 213 224
358. J.M. Estrela, A. Ortega, and E. Obrador Glutathione in cancer biology and therapy Critical reviews in clinical laboratory sciences 43 2006 143 181
359. P.J. O'Dwyer, T.C. Hamilton, K.S. Yao, K.D. Tew, and R.F. Ozols Modulation of glutathione and related enzymes in reversal of resistance to anticancer drugs Hematology/oncology clinics of North America 9 1995 383 396
360. B.A. Jansen, J. Brouwer, and J. Reedijk Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs Journal of inorganic biochemistry 89 2002 197 202
361. J. Zhang, M.A. Antonyak, G. Singh, and R.A. Cerione A mechanism for the upregulation of EGF receptor levels in glioblastomas Cell Rep 3 2013 2008 2020
362. E.S. Wong, J. Lim, B.C. Low, Q. Chen, and G.R. Guy Evidence for direct interaction between Sprouty and Cbl J Biol Chem 276 2001 5866 5875
363. E.S. Wong, C.W. Fong, J. Lim, P. Yusoff, B.C. Low, W.Y. Langdon, and G.R. Guy Sprouty2 attenuates epidermal growth factor receptor ubiquitylation and endocytosis, and consequently enhances Ras/ERK signalling The EMBO journal 21 2002 4796 4808
364. A.B. Hall, N. Jura, J. DaSilva, Y.J. Jang, D. Gong, and D. Bar-Sagi hSpry2 is targeted to the ubiquitin-dependent proteasome pathway by c-Cbl Curr Biol 13 2003 308 314
365. E.Y. Shin, K.S. Shin, C.S. Lee, K.N. Woo, S.H. Quan, N.K. Soung, Y.G. Kim, C.I. Cha, S.R. Kim, D. Park, G.M. Bokoch, and E.G. Kim Phosphorylation of p85 beta PIX, a Rac/Cdc42-specific guanine nucleotide exchange factor, via the Ras/ERK/PAK2 pathway is required for basic fibroblast growth factor-induced neurite outgrowth J. Biol. Chem. 277 2002 44417 44430
366. J.A. Flanders, Q. Feng, S. Bagrodia, M.T. Laux, A. Singavarapu, and R.A. Cerione The Cbl proteins are binding partners for the Cool/Pix family of p21-activated kinase-binding proteins FEBS Lett 550 2003 119 123
367. S.J. Ahn, K.W. Chung, R.A. Lee, I.A. Park, S.H. Lee, D. Park, and E. Noh D. Y. Overexpression of betaPix-a in human breast cancer tissues Cancer Lett. 193 2003 99 107
368. A. Sadok, and C.J. Marshall Rho GTPases: masters of cell migration Small GTPases 5 2014 e29710
369. A. Murali, and K. Rajalingam Small Rho GTPases in the control of cell shape and mobility Cellular and molecular life sciences: CMLS 71 2014 1703 1721
370. J. Lee, I.D. Jung, W.K. Chang, C.G. Park, D.Y. Cho, E.Y. Shin, D.W. Seo, Y.K. Kim, H.W. Lee, J.W. Han, and H.Y. Lee p85 beta-PIX is required for cell motility through phosphorylations of focal adhesion kinase and p38 MAP kinase Experimental cell research 307 2005 315 328
371. J.P. ten Klooster, Z.M. Jaffer, J. Chernoff, and P.L. Hordijk Targeting and activation of Rac1 are mediated by the exchange factor beta-Pix J Cell Biol 172 2006 759 769
372. G. Rosenberger, and K. Kutsche AlphaPIX and betaPIX and their role in focal adhesion formation European journal of cell biology 85 2006 265 274
373. K. Rafiq, J. Guo, L. Vlasenko, X. Guo, M.A. Kolpakov, A. Sanjay, S.R. Houser, and A. Sabri c-Cbl ubiquitin ligase regulates focal adhesion protein turnover and myofibril degeneration induced by neutrophil protease cathepsin G J Biol Chem 287 2012 5327 5339
374. H.Y. Chen, Y.M. Yang, R. Han, and M. Noble MEK1/2 Inhibition Suppresses Tamoxifen Toxicity on CNS Glial Progenitor Cells J Neurosci 33 2013 15069 15074
375. G. Bodoky, C. Timcheva, D.R. Spigel, P.J. La Stella, T.E. Ciuleanu, G. Pover, and N.C. Tebbutt A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy Investigational new drugs 30 2012 1216 1223
376. J.M. Kirkwood, L. Bastholt, C. Robert, J. Sosman, J. Larkin, P. Hersey, M. Middleton, M. Cantarini, V. Zazulina, K. Kemsley, and R. Dummer Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma Clinical cancer research: an official journal of the American Association for Cancer Research 18 2012 555 567
377. S.V. Holt, A. Logie, R. Odedra, A. Heier, S.P. Heaton, D. Alferez, B.R. Davies, R.W. Wilkinson, and P.D. Smith The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models British journal of cancer 106 2012 858 866
378. S.P. Patel, A.J. Lazar, N.E. Papadopoulos, P. Liu, J.R. Infante, M.R. Glass, C.S. Vaughn, P.M. LoRusso, R.B. Cohen, M.A. Davies, and K.B. Kim Clinical responses to selumetinib (AZD6244; ARRY-142886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma Cancer 119 2013 799 805
379. K.B. Reddy, and S. Glaros Inhibition of the MAP kinase activity suppresses estrogen-induced breast tumor growth both in vitro and in vivo International journal of oncology 30 2007 971 975
380. J.E. Le Belle, N.M. Orozco, A.A. Paucar, J.P. Saxe, J. Mottahedeh, A.D. Pyle, H. Wu, and H.I. Kornblum Proliferative neural stem and progenitor cells maintain high endogenous levels of reactive oxygen species which regulate self-renewal and neurogenesis in a PI3K/Akt-dependent manner Cell Stem Cell 8 2011 59 71
381. M. Noble, C. Proschel, and M. Mayer-Proschel Oxidative-reductionist approaches to stem and progenitor cell function Cell Stem Cell 8 2011 1 2
382. H.R. McMurray, E.R. Sampson, G. Compitello, C. Kinsey, L. Newman, B. Smith, S.R. Chen, L. Klebanov, P. Salzman, A. Yakovlev, and H. Land Synergistic response to oncogenic mutations defines gene class critical to cancer phenotype Nature 453 2008 1112 1116
383. B. Smith, and H. Land Anticancer activity of the cholesterol exporter ABCA1 gene Cell reports 2 2012 580 590
384. A. Almudevar, M.N. McCall, H. McMurray, and H. Land Fitting Boolean networks from steady state perturbation data Statistical applications in genetics and molecular biology 10 2011
385. J.M. Ashton, M. Balys, S.J. Neering, D.C. Hassane, G. Cowley, D.E. Root, P.G. Miller, B.L. Ebert, H.R. McMurray, H. Land, and C.T. Jordan Gene sets identified with oncogene cooperativity analysis regulate in vivo growth and survival of leukemia stem cells Cell Stem Cell 11 2012 359 372
386. M. Eberl, S. Klingler, D. Mangelberger, A. Loipetzberger, H. Damhofer, K. Zoidl, H. Schnidar, H. Hache, H.C. Bauer, F. Solca, C. Hauser-Kronberger, A.N. Ermilov, M.E. Verhaegen, C.K. Bichakjian, A.A. Dlugosz, W. Nietfeld, M. Sibilia, H. Lehrach, C. Wierling, and F. Aberger Hedgehog-EGFR cooperation response genes determine the oncogenic phenotype of basal cell carcinoma and tumour-initiating pancreatic cancer cells EMBO molecular medicine 4 2012 218 233
387. I. Riz, T.S. Hawley, T.V. Luu, N.H. Lee, and R.G. Hawley TLX1 and NOTCH coregulate transcription in T cell acute lymphoblastic leukemia cells Mol. Cancer 9 2010 181
388. K. Kaabeche, H. Guenou, D. Bouvard, N. Didelot, A. Listrat, and P.J. Marie Cbl-mediated ubiquitination of alpha5 integrin subunit mediates fibronectin-dependent osteoblast detachment and apoptosis induced by FGFR2 activation J Cell Sci 118 2005 1223 1232
389. N. Sharfe, A. Freywald, A. Toro, and C.M. Roifman Ephrin-A1 induces c-Cbl phosphorylation and EphA receptor down-regulation in T cells J. Immunol. 170 2003 6024 6032
390. B. Sargin, C. Choudhary, N. Crosetto, M.H. Schmidt, R. Grundler, M. Rensinghoff, C. Thiessen, L. Tickenbrock, J. Schwable, C. Brandts, B. August, S. Koschmieder, S.R. Bandi, J. Duyster, W.E. Berdel, C. Muller-Tidow, I. Dikic, and H. Serve Flt3-dependent transformation by inactivating c-Cbl mutations in AML Blood 2007 (in press; blood-2007-01-066076v1)
391. Z. Ahmed, B.J. Smith, and T.S. Pillay The APS adapter protein couples the insulin receptor to the phosphorylation of c-Cbl and facilitates ligand-stimulated ubiquitination of the insulin receptor FEBS Lett. 475 2000 31 34
392. T. Ohrt, A. Mancini, T. Tamura, and R. Niedenthal c-Cbl binds to tyrosine-phosphorylated neurotrophin receptor p75 and induces its ubiquitination Cellular signalling 16 2004 1291 1298
393. L. Penengo, C. Rubin, Y. Yarden, and G. Gaudino c-Cbl is a critical modulator of the Ron tyrosine kinase receptor Oncogene 22 2003 3669 3679
394. P. Soubeyran, A. Barac, I. Szymkiewicz, and I. Dikic Cbl-ArgBP2 complex mediates ubiquitination and degradation of c-Abl The Biochemical journal 370 2003 29 34
395. S. Ye, K. Cihil, D.B. Stolz, J.M. Pilewski, B.A. Stanton, and A. Swiatecka-Urban c-Cbl facilitates endocytosis and lysosomal degradation of cystic fibrosis transmembrane conductance regulator in human airway epithelial cells J Biol Chem 285 2010 27008 27018
396. C.E. Andoniou, N.L. Lill, C.B. Thien, M.L.J. Lupher, S. Ota, D.D. Bowtell, R.M. Scaife, W.Y. Langdon, and H. Band The Cbl proto-oncogene product negatively regulates the Src-family tyrosine kinase Fyn by enhancing its degradation Mol. Cell Biol. 20 2000 851 867
397. C. Dufour, H. Guenou, K. Kaabeche, D. Bouvard, A. Sanjay, and P.J. Marie FGFR2-Cbl interaction in lipid rafts triggers attenuation of PI3K/Akt signaling and osteoblast survival Bone 42 2008 1032 1039
398. A. Sanjay, A. Houghton, L. Neff, E. DiDomenico, C. Bardelay, E. Antoine, J. Levy, J. Gailit, D. Bowtell, W.C. Horne, and R. Baron Cbl associates with Pyk2 and Src to regulate Src kinase activity, alpha(v)beta(3) integrin-mediated signaling, cell adhesion, and osteoclast motility J Cell Biol 152 2001 181 195
399. E.L. Goh, T. Zhu, W.Y. Leong, and P.E. Lobie c-Cbl is a negative regulator of GH-stimulated STAT5-mediated transcription Endocrinology 143 2002 3590 3603